Skip to main content
SpringerLink
Log in

The Cancer Epidemic

Globale Bedeutung der Krebserkrankungen und Situation der onkologischen Bildgebung

The cancer epidemic

Global significance of cancer and the situation in oncological imaging

  • Übersichten
  • Published:
Die Radiologie Aims and scope Submit manuscript

Zusammenfassung

Weltweit wird mit einer erheblichen Zunahme an Krebserkrankungen gerechnet. In Europa wird Krebs bald die häufigste Todesursache sein, d. h. noch vor Herz-Kreislauf-Erkrankungen. Konzertierte Anstrengungen auf wissenschaftlicher, medizinischer, gesellschaftlicher und politischer Ebene werden gefordert, um dieser Problematik globalen Ausmaßes zu begegnen. Hochqualitative onkologische Bildgebung ist dabei von besonderer Bedeutung. Der Zugang dazu hat nachweislich einen signifikanten Einfluss auf die Qualität der Krankenversorgung und das Überleben. Bildgebung ist wesentlicher Bestandteil des Screenings und der Früherkennung. In der klinischen Onkologie ist die Bildgebung unverzichtbar für die multidisziplinäre Diagnostik und personalisierte Therapie. Ebenso ist sie notwendig in der translationalen und klinischen Forschung. Bildgebende Verfahren sind auch selbst Gegenstand der Forschung und Entwicklung und damit auch als Wirtschaftsfaktor von großer Bedeutung. Dieser Artikel möchte Einblicke geben in die globale Problematik der Onkologie und den Beitrag, den die onkologische Bildgebung zu deren Bewältigung leisten kann.

Abstract

A significant increase in the incidence of cancer is expected worldwide. In Europe, cancer will soon be the leading cause of death, ahead of cardiovascular disease. Concerted efforts at the scientific, medical, societal, and political levels are required to address this problem on a global scale. High-quality oncological imaging is of particular importance in this regard. Access to it has been shown to have a significant impact on quality of care and survival. Imaging is an essential component of screening and early detection. In clinical oncology, imaging is essential for multidisciplinary diagnostics and personalized therapy. Likewise, imaging is necessary in translational and clinical research. Imaging techniques are also themselves the subject of research and development and, associated with this, are also of great importance as an economic factor. This article aims to provide insights into the global problem of oncology and the contribution that oncological imaging can make to its management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F (2021) Cancer statistics for the year 2020: an overview. Int J Cancer. https://doi.org/10.1002/ijc.33588

    Article  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

    Article  Google Scholar 

  3. Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, Gavin A, Flego M, Neamtiu L, Dimitrova N, Negrão Carvalho R, Ferlay J, Bettio M (2021) The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer 157:308–347. https://doi.org/10.1016/j.ejca.2021.07.039

    Article  Google Scholar 

  4. https://ec.europa.eu/commission/presscorner/detail/en/ip_21_342. Zugegriffen: 30. Juni 2022

  5. https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf. Zugegriffen: 30. Juni 2022

  6. https://de.statista.com/statistik/daten/studie/185394/umfrage/entwicklung-der-lebenserwartung-nach-geschlecht/. Zugegriffen: 30. Juni 2022

  7. White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ (2014) Age and cancer risk: a potentially modifiable relationship. Am J Prev Med 46(3 Suppl 1):S7–S15. https://doi.org/10.1016/j.amepre.2013.10.029

    Article  Google Scholar 

  8. https://www.cancer.gov/about-cancer/causes-prevention/risk/age. Zugegriffen: 30. Juni 2022

  9. Hehlmann R (2020) Chronic myeloid leukemia in 2020. Hemasphere 4(5):e468. https://doi.org/10.1097/HS9.0000000000000468

    Article  Google Scholar 

  10. Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet 398(10304):1002–1014. https://doi.org/10.1016/S0140-6736(21)01206-X

    Article  CAS  Google Scholar 

  11. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo E Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP; CONCORD Working Group (2018) Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125):1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3

  12. GBD 2019 Cancer Risk Factors Collaborators (2022) The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 400(10352):563–591. https://doi.org/10.1016/S0140-6736(22)01438-6

    Article  Google Scholar 

  13. Zur Hausen H (2019) Cancers in humans: a lifelong search for contributions of infectious agents, autobiographic notes. Annu Rev Virol 6(1):1–28. https://doi.org/10.1146/annurev-virology-092818-015907

    Article  CAS  Google Scholar 

  14. de Villiers EM, Gunst K, Chakraborty D, Ernst C, Bund T, Zur Hausen H (2019) A specific class of infectious agents isolated from bovine serum and dairy products and peritumoral colon cancer tissue. Emerg Microbes Infect 8(1):1205–1218. https://doi.org/10.1080/22221751.2019.1651620

    Article  CAS  Google Scholar 

  15. Peairs KS, Choi Y, Stewart RW, Sateia HF (2017) Screening for breast cancer. Semin Oncol 44(1):60–72. https://doi.org/10.1053/j.seminoncol.2017.02.004

    Article  Google Scholar 

  16. Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK (2021) Lung cancer LDCT screening and mortality reduction—evidence, pitfalls and future perspectives. Nat Rev Clin Oncol 18(3):135–151. https://doi.org/10.1038/s41571-020-00432-6

    Article  Google Scholar 

  17. Kaaks R, Delorme S (2021) Lung cancer screening by low-dose computed tomography—part 1: expected benefits, possible harms, and criteria for eligibility and population targeting. Rofo 193(5):527–536. https://doi.org/10.1055/a-1290-7926

    Article  Google Scholar 

  18. Bick U, Engel C, Krug B, Heindel W, Fallenberg EM, Rhiem K, Maintz D, Golatta M, Speiser D, Rjosk-Dendorfer D, Lämmer-Skarke I, Dietzel F, Schäfer KWF, Leinert E, Weigel S, Sauer S, Pertschy S, Hofmockel T, Hagert-Winkler A, Kast K, Quante A, Meindl A, Kiechle M, Loeffler M, Schmutzler RK, German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) (2019) High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat 175(1):217–228. https://doi.org/10.1007/s10549-019-05152-9

    Article  Google Scholar 

  19. Mann RM, Kuhl CK, Moy L (2019) Contrast-enhanced MRI for breast cancer screening. J Magn Reson Imaging 50(2):377–390. https://doi.org/10.1002/jmri.26654

    Article  Google Scholar 

  20. Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG (2019) Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol 25(13):1550–1559. https://doi.org/10.3748/wjg.v25.i13.1550

    Article  Google Scholar 

  21. Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J (2018) Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA 319(18):1914–1931. https://doi.org/10.1001/jama.2018.3712

    Article  Google Scholar 

  22. Eklund M, Jäderling F, Discacciati A, Bergman M, Annerstedt M, Aly M, Glaessgen A, Carlsson S, Grönberg H, Nordström T, STHLM3 consortium (2021) MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med 385(10):908–920. https://doi.org/10.1056/NEJMoa2100852

    Article  Google Scholar 

  23. Eldred-Evans D, Burak P, Connor MJ, Day E, Evans M, Fiorentino F, Gammon M, Hosking-Jervis F, Klimowska-Nassar N, McGuire W, Padhani AR, Prevost AT, Price D, Sokhi H, Tam H, Winkler M, Ahmed HU (2021) Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study. JAMA Oncol 7(3):395–402. https://doi.org/10.1001/jamaoncol.2020.7456

    Article  Google Scholar 

  24. Nordström T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M, Glaessgen A, Carlsson S, Jäderling F, Eklund M, Grönberg H, STHLM3 study group (2021) Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol 22(9):1240–1249. https://doi.org/10.1016/S1470-2045(21)00348-X

    Article  Google Scholar 

  25. Penkert J, Strüwe FJ, Dutzmann CM, Doergeloh BB, Montellier E, Freycon C, Keymling M, Schlemmer HP, Sänger B, Hoffmann B, Gerasimov T, Blattmann C, Fetscher S, Frühwald M, Hettmer S, Kordes U, Ridola V, Kroiss Benninger S, Mastronuzzi A, Schott S, Nees J, Prokop A, Redlich A, Seidel MG, Zimmermann S, Pajtler KW, Pfister SM, Hainaut P, Kratz CP (2022) Genotype-phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry. J Hematol Oncol 15(1):107. https://doi.org/10.1186/s13045-022-01332-1

    Article  CAS  Google Scholar 

  26. Ignatiadis M, Sledge GW, Jeffrey SS (2021) Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol 18(5):297–312. https://doi.org/10.1038/s41571-020-00457-x

    Article  Google Scholar 

  27. Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA (2019) The need for multi-omics biomarker signatures in precision medicine. Int J Mol Sci 20(19):4781. https://doi.org/10.3390/ijms20194781

    Article  CAS  Google Scholar 

  28. Mayerhoefer ME et al (2020) Introduction to Radiomics. J Nucl Med. https://doi.org/10.2967/jnumed.118.222893

    Article  Google Scholar 

  29. Ward ZJ, Scott AM, Hricak H, Abdel-Wahab M, Paez D, Lette MM, Vargas HA, Kingham TP, Atun R (2020) Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis. Lancet Oncol 21(8):1077–1088. https://doi.org/10.1016/S1470-2045(20)30317-X

    Article  CAS  Google Scholar 

  30. Ward ZJ, Atun R, Hricak H, Asante K, McGinty G, Sutton EJ, Norton L, Scott AM, Shulman LN (2021) The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysis. Lancet Oncol 22(9):1301–1311. https://doi.org/10.1016/S1470-2045(21)00403-4

    Article  Google Scholar 

  31. Schlemmer H, Hohenfellner M (2021) Chancen von KI in der Onkologie am Beispiel der individualisierten Diagnostik und Behandlung von Prostatakrebs. Z Med Ethik 67(3):309–326. https://doi.org/10.14623/zfme.2021.3.309-326

    Article  Google Scholar 

  32. Schlemmer HP (2021) The eye of the CT scanner: the story of learning to see the invisible or from the fluorescent screen to the photon-counting detector. Rofo 193(9):1034–1049. https://doi.org/10.1055/a-1308-2693

    Article  Google Scholar 

  33. Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA, Donoso-Bach L, Frija G, Hierath M, Holmberg O, Khong PL, Lewis JS, McGinty G, Oyen WJG, Shulman LN, Ward ZJ, Scott AM (2021) Medical imaging and nuclear medicine: a lancet oncology commission. Lancet Oncol 22(4):e136–e172. https://doi.org/10.1016/S1470-2045(20)30751-8

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Radiologie, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120, Heidelberg, Deutschland

    Heinz-Peter Schlemmer

Authors
  1. Heinz-Peter Schlemmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heinz-Peter Schlemmer.

Ethics declarations

Interessenkonflikt

H.-P. Schlemmer gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schlemmer, HP. The Cancer Epidemic. Radiologie 63, 49–56 (2023). https://doi.org/10.1007/s00117-022-01092-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00117-022-01092-6

Schlüsselwörter

Keywords

Search

Navigation